Oralair

Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate, the active ingredient in Oralair, is an allergen immunotherapy presented as a sublingual tablet for oral use. It is employed to modify the immune response to grass pollen in patients with allergic rhinitis and related conditions. GNH USA supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oralair is an allergen immunotherapy used to modify the immune response to grass pollen, helping to reduce allergic disease burden.

- Seasonal allergic rhinitis (hay fever): reduces nasal symptoms and the need for rescue medication. - Allergic conjunctivitis: alleviates eye itching, redness and tearing associated with grass pollen exposure. - Grass‑pollen‑triggered mild asthma: may improve symptom control when used as part of a comprehensive allergy management plan.

Oralair may cause local and systemic reactions, most of which are mild and transient.

Common Side Effects: - Oral itching or tingling: mild discomfort in the mouth after administration. - Throat irritation: transient soreness or scratchy sensation. - Ear pruritus: itching in the ears. - Mild gastrointestinal upset: nausea or abdominal discomfort. - Local swelling: mild swelling of the oral mucosa. - Sneezing or mild nasal congestion.

Serious or Rare Side Effects: - Anaphylaxis: severe, potentially life‑threatening allergic reaction. - Systemic allergic reaction: widespread hives, angioedema, or respiratory distress. - Asthma exacerbation: worsening of asthma symptoms. - Severe oral mucosal edema: pronounced swelling that may impair breathing. - Urticaria: widespread hives. - Cardiovascular symptoms: hypotension or tachycardia associated with severe reactions.

Before initiating Oralair, patients should be evaluated for suitability and monitored for adverse reactions.

- Contraindication: severe uncontrolled asthma: avoid use in patients with recent exacerbations. - History of severe allergic reactions: assess risk before starting therapy. - Medical supervision: first dose should be administered under physician observation. - Interaction with other allergen extracts: avoid simultaneous use of different sublingual immunotherapies. - Pregnancy and breastfeeding: discuss potential risks with a healthcare professional. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Oralair may interact with other medications or therapies, influencing safety or efficacy.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of anaphylaxis and complicate emergency treatment. - Immunosuppressive agents: can reduce the effectiveness of allergen immunotherapy. - Concurrent sublingual immunotherapy with different extracts: increased risk of severe local or systemic reactions.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of an allergic reaction. - Systemic corticosteroids: may alter immune response to the extract. - Live vaccines: consider timing to avoid overlapping immune activation. - ACE inhibitors: monitor for angioedema, though risk is low. - NSAIDs: watch for enhanced gastrointestinal irritation.